The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).
Andrea Borghese Apolo
No relevant relationships to disclose
Young H. Lee
No relevant relationships to disclose
Fabiola Cecchi
No relevant relationships to disclose
Piyush K. Agarwal
No relevant relationships to disclose
Howard L. Parnes
No relevant relationships to disclose
Kattie Khadar
No relevant relationships to disclose
Amelia Summerell
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
Kathryn Compton
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose
Donald P. Bottaro
No relevant relationships to disclose